Aura Biosciences, Inc. Shareholders' Equity
Aura Biosciences, Inc. (AURA) had Shareholders' Equity of $315.27 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $315.27M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $107.25M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $136.91M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $156.67M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $315.27M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $107.25M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $136.91M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $156.67M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $174.63M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $127.97M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $151.97M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $174.67M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $191.45M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $208.78M 10-Q · filed 2025-11-13 |
| 2023-12-31 | $225.85M 10-K · filed 2026-03-30 |
| 2023-09-30 | $151.72M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $166.44M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $180.26M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $195.58M 10-K · filed 2025-03-24 |
| 2022-09-30 | $115.05M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $129.09M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $141.09M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $152.31M 10-K · filed 2024-03-27 |
| 2021-09-30 | -$131.01M 10-Q · filed 2022-11-10 |
| 2021-06-30 | -$122.75M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$114.19M 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$108.71M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$104.00M 10-Q · filed 2021-11-24 |
| 2020-06-30 | -$100.58M 10-Q · filed 2021-11-24 |
| 2020-03-31 | -$94.71M 10-Q · filed 2021-11-24 |
| 2019-12-31 | -$87.41M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |